Solei expands successful oil lineup to include Solei Plus+ in Free and Balance Moments.
LEAMINGTON, ON, April 15, 2021 /PRNewswire/ - Aphria Inc. (“Aphria”, “we”, or the “Company”) (TSX: APHA) ( NASDAQ: APHA), a leading global cannabis-lifestyle consumer packaged goods company inspiring and empowering the worldwide community to live their best life, today announced the addition of Good Supply’s THC 30:0 and Solei Plus+ high potency oils to its award-winning adult-use brand portfolio, which join a range of other formats available, including whole dried flower, pre-rolls, oral sprays, soft gels, vapes and topicals.
ADVERTISEMENT
Based on Headset data, high potency oils dominate the category with nine out of the top 10 bottled oils sold being high potency oils1 in BC, Alberta, Saskatchewan and Ontario. To meet this demand, Solei and Good Supply’s new high potency oils offer consumers convenient and versatile options that are distillate-based for a virtually odorless a
Press release content from PR Newswire. The AP news staff was not involved in its creation.
airKAVE Portable Air Purifier Now Approved To Combat COVID-19
April 15, 2021 GMT
AIRKAVE PORTABLE AIR PURIFIER NOW APPROVED TO COMBAT COVID-19
LOS ANGELES, April 15, 2021 /PRNewswire/ airKAVE, the world’s most advanced air purification technology, announced today that the airKAVE Portable passed the Characterization of Model AH01 Air Purification Device in Deactivation of Aerosolized SARS-COV-2 test (from MRIGlobal). The test confirms that airKAVE Portable destroys aerosolized SARS-CoV-2 within a fraction of a second as the air passes through the filterless device providing personal protection against the Coronavirus (COVID-19.) Now available in the U.S., airKAVE Portable is the world’s first SARS-CoV-2 portable antiviral air sanitizer that can be taken with you anywhere you go.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress
Affimed N.V.April 15, 2021 GMT
AFM13 monotherapy: Reported positive data from the preplanned interim analysis for the registration-directed trial in PTCL
AFM13 combination with NK cells: Announced 100% objective response rate in four response evaluable patients, including 2 complete responses
AFM24 monotherapy: AFM24 (phase 1/2a study) completed cohort 4 and is enrolling and treating patients in cohort 5; expansion cohorts expected to start in the second half of 2021
AFM24 combination with NK cells: IND application cleared by the FDA for the combination of AFM24 with NKGen Biotech’s SNK-01 NK autologous cell therapy
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
TILT Holdings Reports Fourth Quarter and Full-Year 2020 Financial Results Including First .
TILT Holdings Inc.April 15, 2021 GMT
Full-year 2020 Adjusted EBITDA of $16.9 million compared to Adjusted EBITDA loss of $0.8 million in 2019
Full-year 2020 cash from operating activities improved $34.2 million compared to 2019
Full-year 2020 cannabis revenue increased 41% compared to 2019
Full-year cash expenses decreased 30% compared to 2019
PHOENIX, April 15, 2021 (GLOBE NEWSWIRE) TILT Holdings Inc. (“TILT” or the “Company”) ( CSE: TILT ) ( OTCQB: TLLTF ) a provider of business solutions to the global cannabis industry that includes inhalation technologies, cultivation, manufacturing, processing, brand development and retail, reported its financial and operating results for the three and twelve-months ended December 31, 2020. All financial information is provided in U.S. dollars e